Australia markets close in 2 hours 5 minutes
  • ALL ORDS

    7,544.60
    +63.90 (+0.85%)
     
  • ASX 200

    7,345.30
    +61.10 (+0.84%)
     
  • AUD/USD

    0.6799
    +0.0004 (+0.05%)
     
  • OIL

    80.52
    -0.03 (-0.04%)
     
  • GOLD

    1,787.60
    +27.70 (+1.57%)
     
  • BTC-AUD

    25,204.65
    +94.29 (+0.38%)
     
  • CMC Crypto 200

    406.13
    +5.44 (+1.36%)
     
  • AUD/EUR

    0.6517
    -0.0000 (-0.01%)
     
  • AUD/NZD

    1.0757
    -0.0022 (-0.20%)
     
  • NZX 50

    11,622.48
    +70.44 (+0.61%)
     
  • NASDAQ

    12,030.06
    +526.61 (+4.58%)
     
  • FTSE

    7,573.05
    +61.05 (+0.81%)
     
  • Dow Jones

    34,589.77
    +737.24 (+2.18%)
     
  • DAX

    14,397.04
    +41.59 (+0.29%)
     
  • Hang Seng

    18,902.54
    +305.31 (+1.64%)
     
  • NIKKEI 225

    28,281.04
    +312.05 (+1.12%)
     

Is AbbVie a Buy?

Is AbbVie a Buy?

Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in July. Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated.